The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need.”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“The development of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 interaction has transformed the therapeutic landscape of patients with advanced non-small cell lung cancer (NSCLC) [1][2][3][4][5][6] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Landmark trials performed on previously treated patients with advanced NSCLC demonstrated superior overall survival (OS) with PD-1/PD-L1 blockade compared to standard chemotherapy [1][2][3] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [72]
In the citing paper
“At the data cut-off, median OS was 9.2 months (95% CI: 7.3-13.3months) on nivolumab compared with 6.0 months (95% CI: 5.1-7.3months) on docetaxel, with a 41% reduction in the risk of death in the nivolumab arm (HR 0.59, 95% CI: 0.44-0.49;P < 0.001).”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“In the phase III trial, nivolumab was better tolerated than docetaxel, with 85% of nivolumab patients receiving at least 90% of their planned dose intensity, compared with 69% of docetaxel patients, together with a treatment discontinuation rate of 10% versus 3% of the patients treated with nivolumab and docetaxel, respectively.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The primary end point was overall response rate, which occurred in 17 (14.5%) of 117 patients (95% CI 8.7 to 22.2).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Median time to response was 3.3 months; median duration of response had not been reached at the time of publication.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Adverse effects included dyspnea, fatigue, pneumonitis, diarrhea, musculoskeletal pain, and severe immune-mediated adverse effects98,99; 59% of patients experienced serious adverse events.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Flagged first, then by citations
Research works printed but not linked: 1
- Soria JC, 2013, Eur J Cancer, 49
Cited by
Sorted by citations
Items 801–900 of 1,048
Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
Kerr, K. M., & Hirsch, F. R. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0522-sa · Cited by 135
Yu, H., Batenchuk, C., Badzio, A., Boyle, T. A., Czapiewski, P., Chan, D. C. F., Lu, X. J. D., Gao, D., Ellison, K. E., Kowalewski, A. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.002 · Cited by 135
Self-citationThrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
Shiuan, E. F., Beckermann, K. E., Özgün, A., Kelly, C. M., McKean, M. A., McQuade, J. L., Thompson, M. A., Puzanov, I. J., Greer, J. P., Rapisuwon, S., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0210-0 · Cited by 135
Godwin, J. L., Jaggi, S., Sirisena, I., Sharda, P., Rao, A. D., Mehra, R., & Veloski, C. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0245-2 · Cited by 135
Li, K., & Tian, H. (2018) · Journal of drug targeting · doi:10.1080/1061186x.2018.1440400 · Cited by 135
Emerging landscape of circular RNAs in lung cancer
Hu, W., Bi, Z., Chen, Z., Liu, C., Li, L., Zhang, F., Zhou, Q. Y., Zhu, W., Song, Y., Zhan, B.-T., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.04.006 · Cited by 135
Pasello, G., Pavan, A., Attili, I., Bortolami, A., Bonanno, L., Menis, J., Conte, P., & Guarneri, V. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102031 · Cited by 135
Zhou, X. M., Jiang, J., Yang, X., Liu, T., Ding, J., Nimmagadda, S., Pomper, M. G., Zhu, H., Zhao, J., Yang, Z., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262045 · Cited by 135
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
Mansfield, A. S., Murphy, S. J., Peikert, T., Yi, E. S., Vasmatzis, G., Wigle, D. A., & Aubry, M. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2246 · Cited by 134
Tartari, F., Santoni, M., Burattini, L., Mazzanti, P., Onofri, A., & Berardi, R. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.06.002 · Cited by 134
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases
Dudnik, E., Yust‐Katz, S., Nechushtan, H., Goldstein, D. A., Zer, A., Flex, D., Siegal, T., & Peled, N. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.031 · Cited by 134
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016
Clark, P. E., Spiess, P. E., Agarwal, N., Bangs, R., Boorjian, S. A., Buyyounouski, M. K., Efstathiou, J. A., Flaig, T. W., Friedlander, T. W., Greenberg, R. E., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0131 · Cited by 134
Johnson, A. M., Bullock, B., Neuwelt, A. J., Poczobutt, J. M., Kaspar, R. E., Li, H. Y., Kwak, J., Hopp, K., Weiser-Evans, M. C. M., Heasley, L. E., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900778 · Cited by 134
Federico, L., McGrail, D. J., Bentebibel, S.-E., Haymaker, C., Ravelli, A., Forget, M., Karpinets, T. V., Jiang, P., Reuben, A., Negrao, M. V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.021 · Cited by 135
Agarwal, Y., Milling, L. E., Chang, J. Y. H., Santollani, L., Sheen, A. M., Lutz, E. A., Tabet, A., Stinson, J. A., Ni, K., Rodrigues, K. A., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00831-9 · Cited by 134
Lechner, A., Schlößer, H., Rothschild, S. I., Thelen, M., Reuter, S., Zentis, P., Shimabukuro‐Vornhagen, A., Theurich, S., Wennhold, K., Garcia-Marquez, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17901 · Cited by 133
Laubli, H. P., Balmelli, C., Kaufmann, L., Stanczak, M. A., Syedbasha, M., Vogt, D., Hertig, A., Müller, B. P., Gautschi, O. P., Stenner, F., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0353-7 · Cited by 133
Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
Moya‐Horno, I., Viteri, S., Karachaliou, N., & Rosell, R. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017745012 · Cited by 134
Gettinger, S. N., Wurtz, A., Goldberg, S. B., Rimm, D. L., Schalper, K. A., Kaech, S. M., Kavathas, P., Chiang, A. C., Lilenbaum, R., Zelterman, D. A., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.03.008 · Cited by 132
Nakaya, A., Kurata, T., Yoshioka, H., Takeyasu, Y., Niki, M., Kibata, K., Satsutani, N. M., Ogata, M., Miyara, T., & Nomura, S. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1250-2 · Cited by 132
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
Liu, X., & Qin, S. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-io-s1-s01 · Cited by 132
Gomez‐Roca, C., Cassier, P. A., Zamarin, D., Machiels, J., Perez‐Gracia, J. L., Hodi, F. S., Taus, Á., Martinez‐García, M., Boni, V., Eder, J. P., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004076 · Cited by 134
de Rodas, M. L., Nagineni, V., Ravi, A., Datar, I. J., Mino-Kenudson, M. A., Corredor, G., Barrera, C., Behlman, L., Rimm, D. L., Herbst, R. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004440 · Cited by 132
Self-citationThe Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs
Kim, S. T., Ha, S. Y., Lee, S., Ahn, S., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Kim, K., et al. (2016) · Journal of Cancer · doi:10.7150/jca.13711 · Cited by 131
Berghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K. U., Birner, P., Bartsch, R., & Preusser, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2216-8 · Cited by 131
Guan, J., Lim, K. S., Mekhail, T. M., & Chang, C.-C. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0361-ra · Cited by 131
The Evolution of Therapies in Non-Small Cell Lung Cancer
Boolell, V., Alamgeer, M., Watkins, D. N., & Ganju, V. (2015) · Cancers · doi:10.3390/cancers7030864 · Cited by 130
Planchard, D., Yokoi, T., McCleod, M., Fischer, J. R., Kim, Y., Ballas, M. S., Shi, K., & Soria, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.003 · Cited by 130
Hecht, M., Büttner-Herold, M. J., Erlenbach‐Wünsch, K., Haderlein, M., Croner, R. S., Grützmann, R., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.015 · Cited by 130
Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 130
Kiyota, N., Hasegawa, Y., Takahashi, S., Yokota, T., Yen, C.-J., Iwae, S., Shimizu, Y., Hong, R., Goto, M., Kang, J. H., et al. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.07.023 · Cited by 130
PD-L1 is an activation-independent marker of brown adipocytes
Ingram, J. R., Dougan, M. L., Rashidian, M., Knoll, M., Keliher, E. J., Garrett, S., Garforth, S., Blomberg, O. S., Espinosa, C. A., Bhan, A. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00799-8 · Cited by 130
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 130
Hyperprogression under Immunotherapy
Frélaut, M., Tourneau, C. L., & Borcoman, É. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112674 · Cited by 130
Immune checkpoint inhibitors win the 2018 Nobel Prize
Huang, P., & Chang, J. W. (2019) · Biomedical Journal · doi:10.1016/j.bj.2019.09.002 · Cited by 130
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Targeted Therapy and Immunotherapy for Lung Cancer
Naylor, E. C., Desani, J., & Chung, P. K. (2016) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2016.02.011 · Cited by 129
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells
Johnson, R. M. G., & Dong, H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00961 · Cited by 131
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1
Bertucci, F., & Gonçalvès, A. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0627-0 · Cited by 129
Telomerase-Targeted Cancer Immunotherapy
Mizukoshi, E., & Kaneko, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081823 · Cited by 129
Wen, W. X., & Leong, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0215381 · Cited by 129
Redman, M. W., Papadimitrakopoulou, V. A., Minichiello, K., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Vokes, E. E., Ramalingam, S. S., Leighl, N. B., Bradley, J. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30475-7 · Cited by 129
Self-citationQuan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 129
Pulmonary sarcoid-like granulomatosis induced by nivolumab
Montaudié, H., Pradelli, J., Passeron, T., Lacour, J. ‐., & Leroy, S. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14808 · Cited by 128
Yamazaki, N., Kiyohara, Y., Uhara, H., Iizuka, H., Uehara, J., Otsuka, F., Fujisawa, Y., Takenouchi, T., Isei, T., Iwatsuki, K., et al. (2017) · Cancer Science · doi:10.1111/cas.13226 · Cited by 128
Nakanishi, Y., Masuda, T., Yamaguchi, K., Sakamoto, S., Horimasu, Y., Nakashima, T., Miyamoto, S., Tsutani, Y., Iwamoto, H., Fujitaka, K., et al. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.05.002 · Cited by 128
Levra, M. G., Cotté, F.-E., Corre, R., Calvet, C. Y., Gaudin, A.-F., Penrod, J. R., Grumberg, V., Jouaneton, B., Jolivel, R., Assié, J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.12.017 · Cited by 128
Liu, F., Qin, L., Liao, Z., Song, J., Yuan, C., Liu, Y., Wang, Y., Xu, H., Zhang, Q., Pei, Y., et al. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00165-3 · Cited by 130
Nagasaki, J., Togashi, Y., Sugawara, T., Itami, M., Yamauchi, N., Yuda, J., Sugano, M., Ohara, Y., Minami, Y., Nakamae, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002098 · Cited by 128
Ahmed, K. A., Kim, S., Arrington, J. A., Naghavi, A. O., Dilling, T. J., Creelan, B., Antonia, S. J., Caudell, J. J., Harrison, L. B., Sahebjam, S., et al. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2437-5 · Cited by 127
Self-citationGuan, X., Zhang, C., Zhao, J., Sun, G., Song, Q., & Jia, W. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.012 · Cited by 128
Consensus for HER2 alterations testing in non-small-cell lung cancer
Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D., Wang, Z., Chu, Q., Mack, P. C., Cheng, Y., Duan, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100395 · Cited by 127
Immune therapies in pancreatic ductal adenocarcinoma: Where are we now?
Hilmi, M., Bartholin, L., & Neuzillet, C. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i20.2137 · Cited by 126
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes
Nagasaki, J., Inozume, T., Sax, N., Ariyasu, R., Ishikawa, M., Yamashita, K., Kawazu, M., Ueno, T., Irie, T., Tanji, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110331 · Cited by 126
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 131
PD-L1 expression in neuroendocrine tumors of the lung
Tsuruoka, K., Horinouchi, H., Goto, Y., Kanda, S., Fujiwara, Y., Nokihara, H., Yamamoto, N., Asakura, K., Nakagawa, K., Sakurai, H., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.03.006 · Cited by 125
Peptide-based materials for cancer immunotherapy
Zhang, L., Huang, Y., Lindstrom, A. R., Lin, T., Lam, K. S., & Li, Y. (2019) · Theranostics · doi:10.7150/thno.37194 · Cited by 125
Clinical pharmacology considerations for the development of immune checkpoint inhibitors
Sheng, J., Srivastava, S., Sanghavi, K., Lu, Z., Schmidt, B. J., Bello, A., & Gupta, M. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.990 · Cited by 124
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli, A., Cerbelli, B., Lionetto, L., Zizzari, I., Salati, M., Pisano, A., Federica, M., Simmaco, M., Nuti, M., & Marchetti, P. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1595-3 · Cited by 124
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 124
Abdel-Rahman, O. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.03.007 · Cited by 124
Chao, H., Berman, A. T., Simone, C. B., Ciunci, C. A., Gabriel, P. E., Lin, H., Both, S., Langer, C. J., Lelionis, K., Rengan, R., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.018 · Cited by 124
Zappasodi, R., Budhu, S., Hellmann, M. D., Postow, M. A., Şenbabaoğlu, Y., Manne, S., Gasmi, B., Liu, C., Zhong, H., Li, Y., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.09.007 · Cited by 124
Li, R., Ong, S. L., Tran, L. M., Jing, Z., Liu, B., Park, S. J., Huang, Z. L., Walser, T. C., Heinrich, E. L., Lee, G., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-57285-y · Cited by 124
Ghini, V., Laera, L., Fantechi, B., Monte, F. D., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020) · Cancers · doi:10.3390/cancers12123574 · Cited by 124
Maekawa, N., Konnai, S., Nishimura, M., Kagawa, Y., Takagi, S., Hosoya, K., Ohta, H., Kim, S., Okagawa, T., Izumi, Y., et al. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00147-6 · Cited by 124
Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
Alturki, N. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134301 · Cited by 127
Costa, R., Carneiro, B. A., Agulnik, M., Rademaker, A. W., Pai, S. G., Villaflor, V. M., Cristofanilli, M., Sosman, J. A., & Giles, F. J. (2017) · Oncotarget · doi:10.18632/oncotarget.13315 · Cited by 123
Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1375642 · Cited by 123
Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes
Lizotte, P. H., Ivanova, E. V., Awad, M. M., Jones, R. E., Keogh, L., Liu, H., Dries, R., Almonte, C. G., Herter-Sprie, G. S., Santos, A. A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.89014 · Cited by 123
Immune checkpoint inhibitors in advanced non–small cell lung cancer
Assi, H. I., Kamphorst, A. O., Moukalled, N. M., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31105 · Cited by 123
Lazzari, C., Karachaliou, N., Bulotta, A., Viganò, M., Mirabile, A., Brioschi, E., Santarpía, M., Gianni, L., Rosell, R., & Gregorc, V. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918762094 · Cited by 123
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 123
Shoji, F., Takeoka, H., Kozuma, Y., Toyokawa, G., Yamazaki, K., Ichiki, M., & Takeo, S. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.08.006 · Cited by 124
Proteogenomic landscape of squamous cell lung cancer
Stewart, P. A., Welsh, E. A., Slebos, R. J. C., Fang, B., Izumi, V., Chambers, M., Zhang, G., Cen, L., Pettersson, F. H., Zhang, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11452-x · Cited by 125
Computational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B. D., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 123
Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing
Cohen, D. B., Hondelink, L. M., Solleveld‐Westerink, N., Kolkman-Uljee, S. M., Ruano, D., Cleton-Jansen, A., von der Thüsen, J. H., Ramai, S. R. S., Postmus, P. E., van Roggen, J. F. G., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.019 · Cited by 123
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Lim, S. M., Hong, M. H., & Kim, H. R. (2020) · Immune Network · doi:10.4110/in.2020.20.e10 · Cited by 123
Yang, F., Markovic, S. N., Molina, J. R., Halfdanarson, T. R., Pagliaro, L. C., Chintakuntlawar, A. V., Li, R., Wei, J., Wang, L., Liu, B., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.12534 · Cited by 124
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 123
Sivapalan, L., Murray, J. C., Canzoniero, J. V., Landon, B., Jackson, J., Scott, S., Lam, V., Levy, B. P., Sausen, M., & Anagnostou, V. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005924 · Cited by 122
Yang, C., Lin, M., Chang, Y., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.12.033 · Cited by 122
PD ‐1/ PD ‐L1 inhibitors in haematological malignancies: update 2017
Jelı́nek, T., Mihályová, J., Kaščák, M., Ďuraš, J., & Hájek, R. (2017) · Immunology · doi:10.1111/imm.12788 · Cited by 122
Wei, J. S., Kuznetsov, I. B., Zhang, S., Song, Y., Asgharzadeh, S., Sindiri, S., Wen, X., Patidar, R., Najaraj, S., Walton, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0599 · Cited by 122
Jiang, M., Sun, D., Guo, Y., Guo, Y., Xiao, J., Wang, L., & Yao, X. (2019) · Academic Radiology · doi:10.1016/j.acra.2019.04.016 · Cited by 122
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Tu, E., McGlinchey, K., Wang, J., Martin, P., Ching, S., Floc’h, N., Kurasawa, J. H., Starrett, J. H., Lazdun, Y., Wetzel, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.142843 · Cited by 125
Prasad, V. K., & Kaestner, V. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.06.007 · Cited by 121
Queirolo, P., & Spagnolo, F. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.07.002 · Cited by 121
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Liu, B., Song, Y., & Liu, D. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0541-9 · Cited by 122
Ritchie, G. E., Gasper, H. M., Man, J., Lord, S. J., Marschner, I. C., Friedlander, M. L., & Lee, C. K. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5236 · Cited by 121
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 121
Sun, W. Y., Lee, Y. K., & Koo, J. S. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0925-6 · Cited by 120
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership
Chajon, É., Castelli, J., Marsiglia, H. R., & de Crevoisier, R. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.017 · Cited by 120
Chang, Y., Yang, C., Lin, M., Wu, C., & Yang, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.012 · Cited by 119
Shien, K., Papadimitrakopoulou, V. A., & Wistuba, I. I. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.016 · Cited by 119
Leprieur, E. G., Duménil, C., Julié, C., Giraud, V., Dumoulin, J., Labrune, S., & Chinet, T. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.041 · Cited by 119
PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Müller, T., Braun, M., Dietrich, D., Aktekin, S., Höft, S., Kristiansen, G., Göke, F., Schröck, A., Brägelmann, J., Held, S. A. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17547 · Cited by 119
The Future of Immune Checkpoint Cancer Therapy After PD-1 and CTLA-4
Hahn, A. W., Gill, D. M., Pal, S. K., & Agarwal, N. (2017) · Immunotherapy · doi:10.2217/imt-2017-0024 · Cited by 119
Metadata
- Authors
- Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R.
- Affiliations
- City Of Hope National Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Perugia (IT)
- Ruhrlandklinik (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Oncology Hematology Care (US)
- Duke Medical Center (US)
- Massachusetts General Hospital (US)
- Fakultní nemocnice Bulovka (CZ)
- University Hospital Heidelberg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Amphia Ziekenhuis (NL)
- Hospital Universitario Virgen del Rocío (ES)
- LungenClinic Grosshansdorf (DE)
- Bristol-Myers Squibb (United States) (US)
- Tennessee Oncology (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-09
- Volume
- 373
- Issue
- 2
- Pages
- 123-135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4681400
- OpenAlex
- W2156353875
- Cited by
- 8,447
- References
- 22
- Citations by year
- 2026: 204 · 2025: 332 · 2024: 525 · 2023: 627 · 2022: 718 · 2021: 928 · 2020: 1065 · 2019: 969 · 2018: 1066 · 2017: 1001 · 2016: 803 · 2015: 184
- FWCI
- 444.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, docetaxel, squamous cell non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, overall survival, progression-free survival, PD-L1 expression, treatment-related adverse events, second-line therapy, previously treated patients, response rate, treatment safety and efficacy comparison, immunotherapy versus chemotherapy
- MeSH terms
- Docetaxel, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Immunoglobulin G, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Taxoids, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
